Stock Events

Stock Events

Healios K.K. 

$1.8000
12
-$0.90-33.33% Tuesday 20:00

Statistics

Day High
2.7
Day Low
2.7
52W High
4.15
52W Low
1.8
Volume
100
Avg. Volume
19
Mkt Cap
208.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.19
-0.09
0.02
0.12
Expected EPS
-0.0784363
Actual EPS
N/A

Financials

-789.64%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
3.82MRevenue
-30.19MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HLOSF. It's not an investment recommendation.
Mitsubishi UFJ Financial Group
6
8306.TSE
ENEOS
4
5020.TSE
Japan Tobacco
3
2914.TSE
Mitsubishi HC Capital
3
8593.TSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.2B
Mesoblast Limited specializes in developing regenerative medicine products, which puts them in direct competition with Healios in the cell therapy market.
Biolife Solutions
BLFS
Mkt Cap1.81B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, which are essential for companies like Healios, positioning them as indirect competitors.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics AG is focused on gene editing and gene therapy, areas that overlap with Healios's work in regenerative medicine and cell therapy.
Editas Medicine
EDIT
Mkt Cap477.63M
Editas Medicine, Inc. is involved in gene editing, a cutting-edge area of biotechnology that competes with Healios's regenerative medicine and cell therapy technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics, Inc. specializes in CRISPR/Cas9 gene editing, competing in the broader market of genetic and cell therapy that Healios is also targeting.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, some of which may compete with Healios's products in the regenerative medicine market.

About

Healios K.K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States. The company's robust pipeline features several advanced cellular and tissue-based therapies: iPSC-derived regenerative medicines HLCR011 and HLCR012, which target age-related macular degeneration; HLCL041, an iPSC regenerative medicine for metabolic liver disease; HLCM051, a regenerative treatment for ischemic stroke and acute respiratory distress syndrome; and HLCN061, currently under development for solid tumor indications. Furthermore, Healios K.K. maintains a collaborative research agreement with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies for mesothelioma. Founded in 2011 as Retina Institute Japan, K.K., the company rebranded to Healios K.K. in September 2013 and is headquartered in Tokyo, Japan.
Show more...
CEO
Tadahisa S. Kagimoto
Employees
75
Country
Japan
ISIN
JP3835100003
WKN
000A14U80

Listings

F
DE
6VX.F
TSE
JP
4593.TSE
OTC Link
US
HLOSF

0 Comments

Share your thoughts

FAQ

What is Healios K.K. stock price today?▼
The current price of HLOSF is $1.80 USD — it has decreased by -33.33% in the past 24 hours. Watch Healios K.K. stock price performance more closely on the chart.
What is Healios K.K. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Healios K.K. stocks are traded under the ticker HLOSF.
Is Healios K.K. stock price growing?▼
HLOSF stock has risen by +0% compared to the previous week, the month change is a -33.33% fall, over the last year Healios K.K. has showed a -56.2% decrease.
What is Healios K.K. market cap?▼
Today Healios K.K. has the market capitalization of 208.31M
When is the next Healios K.K. earnings date?▼
Healios K.K. is going to release the next earnings report on November 18, 2026.
What were Healios K.K. earnings last quarter?▼
HLOSF earnings for the last quarter are 0.06 USD per share, whereas the estimation was -0.01 USD resulting in a +517.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Healios K.K. revenue for the last year?▼
Healios K.K. revenue for the last year amounts to 3.82M USD.
What is Healios K.K. net income for the last year?▼
HLOSF net income for the last year is -30.19M USD.
How many employees does Healios K.K. have?▼
As of August 25, 2026, the company has 75 employees.
In which sector is Healios K.K. located?▼
Healios K.K. operates in the Health & Wellness sector.
When did Healios K.K. complete a stock split?▼
Healios K.K. has not had any recent stock splits.
Where is Healios K.K. headquartered?▼
Healios K.K. is headquartered in Tokyo, Japan.